Stichting Researchfonds Pathologie

Jan Marcus Walboomers

Christophorus Joannes Meijer

Adrianus Johannes Van Den Brule

Petrus Josephus Snijders

The oligonucleotides: (i) the 23-mer 5&prime;-TTTGTTACTGTGGTAGATACTAC-3&prime; (SEQ ID NO: 1) or the 23-mer which is complementary to it; (ii) a 23-mer derived from (i) by from 1 to 5 nucleotide substitutions; (iii) a 23 -mer having a 3&prime; terminal sequence consisting of (i) or (ii); (iv) a fragment of (i) or (ii) having a length of from 8 to 18 nucleotides; (v) the 25-mer 5&prime;-GAAAAATAAACTGTAAATCATATTC-3&prime; (SEQ ID NO: 2) or the 25-mer which is complementary to it; (vi) a 25-mer derived from (v) by from 1 to 5 nucleotide substitutions; (vii) a 25 -mer having a 3&prime; terminal sequence consisting of (v) or (vi); (viii) the 28-mer 5&prime;-GAAAAATAAACTGTAAATCATATTCTTC-3&prime; (SEQ ID NO: 10) or the 28-mer which is complementary to it; (ix) the 28-mer 5&prime;-GAAAAATAAACTGTAAATCATATTCCTC-3&prime; (SEQ ID NO: 18) or the 28-mer which is complementary to it; (x) a 28-mer derived from (viii) or (ix) by from 1 to 5 nucleotide substitutions; (xi) a 28 -mer having a 3&prime; terminal sequence consisting of (viii), (ix) or (x); (xii) a fragment of (v), (vi), (vii), (ix) or (x) having a length of from 8 to 18 nucleotides, useful as a primer in a nuc acid amplification process, e.g. a general primer PCR or NASBA, or LCR, to amplify DNA of genital HPV genotypes, e.g. in a method of analyzing a sample for the presence therein of HPV.

Growing community of inventors

Amsterdam, Netherlands

Jan Marcus Walboomers